16 reports

  • A cohort study of 868 IMD survivors in Canada between 2002-2011
  • 3.1 BIBLIOGRAPHY

Meningococcal disease.

  • Meningococcal
  • Brazil
  • Europe
  • United Kingdom
  • Forecast
  • 6. Latest update
  • 9. General News, Project News
  • Meningococcal
  • Pathology
  • Vaccine
  • Supply
  • GlaxoSmithKline plc
  • MENINGOCOCCAL [SEROTYPE B] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPES C, Y] VACCINE - DRUG PROFILE
  • Meningococcal
  • China
  • United States
  • World
  • Product Initiative
  • 5.1 MENINGOCOCCAL IMMUNIZATION POLICY
  • SYMPTOMS OF MENINGOCOCCAL DISEASE
  • Meningococcal
  • Europe
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • MENINGOCOCCAL [SEROTYPE B] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPE B] VACCINE - DRUG PROFILE
  • Meningococcal
  • Pathology
  • Vaccine
  • United States
  • Product Initiative
  • CAUSES OF MENINGOCOCCAL DISEASES
  • Introduction
  • Meningococcal
  • Market Size
  • Meningococcal group
  • Pfizer Inc.
  • Sanofi S.A.
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • Meningococcal
  • Pharmaceutical
  • United States
  • Product Initiative
  • ContraFect Corporation
  • Menactra for meningococcal disease - SWOT analysis
  • KEY MARKETED VACCINES FOR MENINGOCOCCAL DISEASE
  • Meningococcal
  • Europe
  • GlaxoSmithKline plc
  • Meningococcal group
  • Pfizer Inc.
  • Deal in Brief
  • Deal in Brief
  • Meningococcal
  • China
  • Company
  • M&A
  • Walvax Biotechnology Co., Ltd
  • Clinical Trial profile. 151 Trial Title
  • Clinical Trial profile. 251 Trial Title
  • Clinical Trial
  • Infectious Disease
  • Meningococcal
  • World
  • Sanofi S.A.
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • Meningitis - Drug Profiles
  • Meningococcal
  • Pharmaceutical
  • United States
  • Product Initiative
  • ContraFect Corporation
  • MONO VACCINES
  • MARKET OVERVIEW
  • Meningococcal
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • BACTERIAL (PYOGENIC) MENINGITIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*
  • Clinical Trial profile. 34
  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.
  • Clinical Trial profile. 142 Trial Title
  • Clinical Trial profile. 37 Trial Title
  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Novartis AG
  • Pneumococcal Meningitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • Product Initiative
  • MENINGOCOCCAL [SEROTYPE B] VACCINE
  • INVASIVE MENINGOCOCCAL DISEASE DUE TO NEISSERIA MENINGITIDIS SEROGROUP B IN PERSONS 10 - 25 YEARS OF AGE.
  • Lymphoma
  • Meningococcal
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.